Aim: In this study, the safety and tolerability of paclitaxel and carboplatin (PC) regimen in elderly patients with advanced non-small cell lung cancer (NSCLC) was investigated. Material and Method: Elderly patients (ages amp;ge;70 years) who received PC for stage III (n=11) or IV (n=...
1,8,15,22,29Paclitaxel50mg/m 2 IV Regimendetails 1,8,15,22,29CarboplatinAUC*=2IV *Dose(mg)=targetAUC(mg/ml.min)x[GFR(ml/min)+25] AdministrationGivepre-medication. Paclitaxelshouldbeadministeredbeforecarboplatin. Paclitaxelisadministeredina250mlsodiumchloride0.9%non-PVC ...
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-... PURPOSE: This phase III trial compared the efficacy and safety of albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin with solvent-based...
The impressive activity of this regimen makes it suitable for further investigation in the second-line setting. Toxicity seen in the unfit population mandates some modification of the regimen. 展开 关键词: Non-small cell lung cancer chemotherapy Paclitaxel ...
Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non–small cell lung cancer. JAMA. 2012;307(15):1593-1601. eTable 1. P Values for the Chi-Square Test Comparing Characteristics Between BCP and CP 2006-7 and Between BCP and CP 2002-5 Elderly Advanced ...
The chemotherapy regimen of paclitaxel and carboplatin produces an objective response in 30%-60% of patients with non-small-cell lung cancer (NSCLC). In a prospective study, we administered paclitaxel 200 mg/m2 (by 1-3-hr infusion) and carboplatin at an area under the plasma concentration cu...
Journal for ImmunoTherapy of Cancer https://doi.org/10.1186/s40425-019-0593-1 (2019) 7:122 SHORT REPORT Open Access Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors Sonia Domingos-Pereira1, Gabriele Galliverti2, Douglas...
The combination of paclitaxel and carboplatin has been incorporated as the investigational arm of all the ongoing multicenter and cooperative group studies. While the results from these randomized studies are awaited, this combination has become the most widely used regimen in community practice for ...
The regimen has been well tolerated. One patient had a complete response and 12 had partial responses, for an overall response rate of 50%. There is a suggestion of a dose-response effect with both paclitaxel and carboplatin. The combination of paclitaxel and carboplatin is active in non-...
Paclitaxel and carboplatin upregulate thymidine phosphorylase and thus may provide synergistic antitumor activity in combination with capecitabine (CTX). We, therefore, performed a phase I/II study of CTX. In the phase I study, patients with advanced solid tumors received carboplatin on day 1, pacli...